Non-cirrhotic portal hypertension – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:31:15 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Non-cirrhotic portal hypertension – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Apixaban for Patients with Intrahepatic Non-Cirrhotic Portal Hypertension https://clinicaltrials.eu/trial/study-on-apixaban-for-patients-with-intrahepatic-non-cirrhotic-portal-hypertension/ Wed, 29 Apr 2026 14:27:28 +0000 https://clinicaltrials.eu/trial/study-on-apixaban-for-patients-with-intrahepatic-non-cirrhotic-portal-hypertension/ This clinical trial is focused on studying a condition known as intrahepatic non-cirrhotic portal hypertension (INCPH). This is a liver-related condition where there is high blood pressure in the portal vein system, which carries blood from the digestive organs to the liver, but it occurs without the presence of liver cirrhosis. The trial will evaluate the effects of a medication called apixaban, which is a blood thinner, to see if it can help prevent or reduce the formation of blood clots in the portal vein system. Participants in the study will receive either Eliquis 2.5 mg film-coated tablets, which contain apixaban, or a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to assess the impact of taking apixaban over a period of 24 months on the development or worsening of blood clots in the portal vein system. This includes areas such as the splenic and mesenteric veins, as well as the main portal vein and its branches. The study will involve regular check-ups and imaging tests, such as CT scans, to monitor the condition of the veins and ensure the safety and well-being of the participants.

Participants will be randomly assigned to receive either the active medication or the placebo, and neither the participants nor the researchers will know which treatment each participant is receiving. This approach helps to ensure that the results of the study are unbiased and reliable. The trial is expected to last for about two years, during which time participants will be closely monitored for any changes in their condition.

]]>